The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1

Lisa Derosa; Bertrand Routy; Guido Guido Kroemer; Laurence Zitvogel

doi:10.1080/2162402x.2018.1434468

Abstract

1 min read

Cancer immunotherapists have been searching for biomarkers predicting patient responses to PD-1/PD-L1 blockade in neoplastic cells as well as in the immune system. Now, accumulating evidence indicates that the composition of the intestinal microflora has a major impact on patient prognosis. Here, we enumerate the bacterial species that are associated with favorable outcome of immunotherapy.

Related publications

Editorial Material2019

Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade

Oliver Kepp, Laurence Zitvogel, Guido Guido Kroemer

Article2018

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade

Joy Hsu, Jonathan J. Hodgins, Malvika Marathe, Chris J. Nicolai, Marie‐Claude Bourgeois‐Daigneault, Troy N. Trevino, Camillia S. Azimi, Amit Scheer, Haley E. Randolph, Thornton W. Thompson, Lily Zhang, Alexandre Iannello, Nikhita Mathur, Karen Jardine, Georgia Kirn, John C. Bell, Michael W. McBurney, David H Raulet, Michele Ardolino

Article2025

Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients

Jianzhou Chen, Antonin Lévy, Ai-Ling Tian, Xuehan Huang, Guoxin Cai, Marine Fidelle, Conrad Rauber, Pierre Ly, Eugénie Pizzato, Lisa Sitterlé, Gianmarco Piccinno, Peng Liu, Sylvère Durand, Misha Mao, Liwei Zhao, Valerio Iebba, Hannah Felchle, Anne-Laure Mallard de La Varende, Julius C. Fischer, Simon Thomas, Tim F. Greten, Jennifer Jones, Cecilia Monge, Sandra Demaria, ,

Article2014

<scp>PD</scp> ‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐ <scp>PD</scp> ‐1/ <scp>PD</scp> ‐ <scp>L</scp> 1 clinical trials

Jason Madore, Ricardo E. Vilain, Alexander M. Menzies, Hojabr Kakavand, James S. Wilmott, Jessica Hyman, Jennifer H. Yearley, Richard Kefford, John F. Thompson, Georgina V. Long, Peter Hersey, Richard A Scolyer

Article2020

Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD−1/PD-L1 Checkpoint Blockade

Tomoko Aoki, Masatoshi Kudo, Kazuomi Ueshima, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Hiroshi Ida, Yasunori Minami, Masakatsu Tsurusaki, Naoshi Nishida